MedPath

Levosimendan

Generic Name
Levosimendan
Drug Type
Small Molecule
Chemical Formula
C14H12N6O
CAS Number
141505-33-1
Unique Ingredient Identifier
C6T4514L4E
Background

Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

Indication

For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.

Associated Conditions
Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure
Associated Therapies
Positive cardiac inotropic effect, Intravenous inotropic therapy
Clinical Trials
Related News

Levosimendan In Patients Undergoing LVAD Implantation

Conditions
Biventricular Failure
Left Ventricular Dysfunction
Right Ventricular Dysfunction
Interventions
First Posted Date
2018-09-06
Last Posted Date
2020-04-03
Lead Sponsor
University Hospital Dubrava
Target Recruit Count
50
Registration Number
NCT03659851
Locations
🇭🇷

Nikola Bradic, Zagreb, Croatia

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Phase 2
Conditions
Hypertension Pulmonary Secondary Heart Failure
Right Sided Heart Failure With Normal Ejection Fraction
Heart Failure With Normal Ejection Fraction
Interventions
First Posted Date
2018-08-09
Last Posted Date
2021-04-30
Lead Sponsor
Tenax Therapeutics, Inc.
Target Recruit Count
36
Registration Number
NCT03624010
Locations
🇺🇸

Stanford Healthcare, Stanford, California, United States

🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

🇺🇸

UW Health University Hospital, Madison, Wisconsin, United States

and more 6 locations

Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart Failure

Phase 4
Conditions
Heart Failure
Interventions
Drug: Placebo
First Posted Date
2018-07-03
Last Posted Date
2019-07-17
Lead Sponsor
Finn Gustafsson
Target Recruit Count
42
Registration Number
NCT03576677
Locations
🇩🇰

Department of Cardiology, The Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

🇩🇰

Department of Cardiology, Odense University Hospital, Odense, Denmark, Odense, Denmark

🇩🇰

Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark, Herlev, Denmark

Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries

Phase 2
Completed
Conditions
Heart Failure
Interventions
Drug: Saline
First Posted Date
2018-06-14
Last Posted Date
2018-06-14
Lead Sponsor
National Cancer Institute, Egypt
Target Recruit Count
60
Registration Number
NCT03557255
Locations
🇪🇬

Department of Anesthesia and Pain medicine.National Cancer Institute, Cairo, Egypt

Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX

Phase 3
Conditions
Acute Decompensated Heart Failure
Interventions
First Posted Date
2018-06-13
Last Posted Date
2021-05-11
Lead Sponsor
Yooyoung Pharmaceutical Co., Ltd.
Target Recruit Count
112
Registration Number
NCT03555123
Locations
🇰🇷

Severance Hospital, Seoul, Korea, Republic of

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Phase 2
Completed
Conditions
Hypertension Pulmonary Secondary
Heart Failure, Right Sided
Heart Failure With Normal Ejection Fraction
Interventions
Drug: Matching Placebo
First Posted Date
2018-05-30
Last Posted Date
2024-11-20
Lead Sponsor
Tenax Therapeutics, Inc.
Target Recruit Count
44
Registration Number
NCT03541603
Locations
🇺🇸

North Shore University Hospital, Manhasset, New York, United States

🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 13 locations

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS

Phase 3
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
First Posted Date
2018-04-20
Last Posted Date
2022-05-11
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
496
Registration Number
NCT03505021
Locations
🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

🇨🇦

Moncton Hospital, Southeast Regional Health Authority, Moncton, New Brunswick, Canada

🇺🇸

Hospital for Special Care, New Britain, Connecticut, United States

and more 101 locations

Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure

Phase 3
Conditions
Heart Failure
Interventions
Drug: Placebos
First Posted Date
2018-02-19
Last Posted Date
2018-08-22
Lead Sponsor
Dr. Gerhard Pölzl
Target Recruit Count
264
Registration Number
NCT03437226
Locations
🇦🇹

Medical University Innsbruck, Innsbruck, Tirol, Austria

Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions

Not Applicable
Withdrawn
Conditions
Myocardial Infarction
Outcome
Interventions
First Posted Date
2017-01-18
Last Posted Date
2022-10-27
Lead Sponsor
RWTH Aachen University
Registration Number
NCT03022877

Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure

Conditions
Heart Decompensation
First Posted Date
2016-11-25
Last Posted Date
2018-05-16
Lead Sponsor
Tenax Therapeutics, Inc.
Registration Number
NCT02973620
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy